Kapil Dhingra - 01 Jan 2025 Form 3 Insider Report for LAVA Therapeutics NV (LVTX)

Role
Director
Signature
/s/ Amy Garabedian, Attorney-in-Fact
Issuer symbol
LVTX
Transactions as of
01 Jan 2025
Net transactions value
$0
Form type
3
Filing time
02 Jan 2025, 09:26:47 UTC
Previous filing
06 Jun 2024
Next filing
18 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding LVTX Common Shares 30,000 01 Jan 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding LVTX Share Options (Right to Buy) 01 Jan 2025 Common Shares 104,754 $8.14 Direct F1, F2
holding LVTX Share Options (Right to Buy) 01 Jan 2025 Common Shares 102,986 $8.14 Direct F2, F3
holding LVTX Share Options (Right to Buy) 01 Jan 2025 Common Shares 20,000 $5.10 Direct F4
holding LVTX Share Options (Right to Buy) 01 Jan 2025 Common Shares 20,000 $3.64 Direct F4
holding LVTX Share Options (Right to Buy) 01 Jan 2025 Common Shares 33,390 $1.59 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying the option vest in 48 equal monthly installments beginning on February 26, 2021, provided the Reporting Person remains in a service relationship with the Issuer or a subsidiary of the Issuer on each such vesting date.
F2 Converted to U.S. dollars based on an exchange rate of 1.00 euro = $1.0389 (rounded to the nearest whole cent), the foreign exchange reference rate on December 31, 2024 as reported by the European Central Bank. Each option may be exercised for a price of 7.84 euros per share.
F3 The shares underlying the option vest in 48 equal monthly installments beginning on March 17, 2021, provided the Reporting Person remains in a service relationship with the Issuer or a subsidiary of the Issuer on each such vesting date.
F4 Fully vested and immediately exercisable.
F5 100% of the shares underlying the option will vest on January 19, 2025, provided the Reporting Person remains in a service relationship with the Issuer or a subsidiary of the Issuer on such vesting date.